Allogene Therapeutics (ALLO) Price & Analysis

Compare

1,439 Followers

ALLO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.86 - $3.78

Previous CloseN/A

Volume1.66M

Average Volume (3M)3.62M

Market Cap

$319.35M

Enterprise Value$419.05M

Total Cash (Recent Filing)$280.04M

Total Debt (Recent Filing)$81.29M

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Aug 06, 2025

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding218,730,800

10 Day Avg. Volume2,675,259

30 Day Avg. Volume3,622,299

Financial Highlights & Ratios

PEG Ratio-0.10

Price to Book (P/B)1.35

Price to Sales (P/S)0.00

P/FCF Ratio-3.99

Enterprise Value/Market Cap1.31

Enterprise Value/Revenue-9.52K

Enterprise Value/Gross Profit-19.05K

Enterprise Value/Ebitda-0.42

Forecast

1Y Price Target

$7.77

Price Target Upside435.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Allogene Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyALLO-316 Phase 1b data at ASCO demonstrates consistent efficacy and safety in a hard-to-treat ccRCC population.

Financial PositionAllogene currently has $335.5M cash and cash equivalents, and lowered cash burn for FY25 to $150M, extending cash runway into 2H27 for the key ALPHA3 readout.

Technological ValidationALLO-316's results are encouraging and validating of the Dagger technology.

Bears Say

Clinical DelaysThe clinical delay for ALPHA3 was driven by slower-than-expected transitions from site activation to initiation of patient screening.

Comparative SafetySafety in Phase 1b cohort is consistent with Ph1a study with no new grade 5 and dose-limiting toxicities events, but slightly inferior to belzutifan.

Market ValuationALLO is trading well below cash value, reflecting zero value currently ascribed to the company’s pipeline.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

10.77% Insiders

18.41% Mutual Funds

47.35% Other Institutional Investors

15.53% Public Companies and Individual Investors

Detailed Ownership Overview >

ALLO FAQ

What was Allogene Therapeutics Inc’s price range in the past 12 months?

Allogene Therapeutics Inc lowest stock price was $0.86 and its highest was $3.78 in the past 12 months.

What is Allogene Therapeutics Inc’s market cap?

Allogene Therapeutics Inc’s market cap is $319.35M.

When is Allogene Therapeutics Inc’s upcoming earnings report date?

Allogene Therapeutics Inc’s upcoming earnings report date is Aug 06, 2025 which is in 54 days.

How were Allogene Therapeutics Inc’s earnings last quarter?

Allogene Therapeutics Inc released its earnings results on May 13, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.01.

Is Allogene Therapeutics Inc overvalued?

According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Allogene Therapeutics Inc pay dividends?

Allogene Therapeutics Inc does not currently pay dividends.

What is Allogene Therapeutics Inc’s EPS estimate?

Allogene Therapeutics Inc’s EPS estimate is -0.27.

How many shares outstanding does Allogene Therapeutics Inc have?

Allogene Therapeutics Inc has 218,730,800 shares outstanding.

What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?

Allogene Therapeutics Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -15.929%.

Which hedge fund is a major shareholder of Allogene Therapeutics Inc?

Currently, no hedge funds are holding shares in ALLO

Allogene Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-59.60%

Trailing 12-Months

Asset Growth

-13.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Allogene Therapeutics Inc

Allogene Therapeutics, Inc. (ALLO) is a biotechnology company dedicated to developing and commercializing allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer. The company operates in the healthcare sector, focusing on innovative cell therapy products that harness the power of the immune system to treat and potentially cure cancer. Allogene's core products leverage proprietary gene-editing technology to create off-the-shelf CAR T-cell therapies designed to target a broad range of hematologic and solid tumors.

ALLO Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlights significant progress in clinical trials and financial management, with strong site engagement and promising data, particularly in the ALPHA3 and ALLO-316 programs. However, operational delays and financial losses present challenges. Overall, the sentiment reflects a balanced view with optimism for future achievements.Read More>

ALLO Stock 12 Month Forecast

Average Price Target

$7.77

▲(435.86%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,2.249230769230769,3.2284615384615387,4.207692307692308,5.186923076923077,6.166153846153847,7.145384615384616,8.124615384615385,9.103846153846154,10.083076923076923,11.062307692307693,12.041538461538462,13.02076923076923,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.77,2.27,2.77,3.27,3.77,4.27,4.77,5.27,5.77,6.27,6.77,7.27,{"y":7.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.3646153846153846,1.4592307692307693,1.5538461538461539,1.6484615384615384,1.7430769230769232,1.8376923076923077,1.9323076923076923,2.026923076923077,2.121538461538462,2.216153846153846,2.310769230769231,2.4053846153846155,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >